XCUR - EXICURE, INC.
IEX Last Trade
5.7
0 0%
Share volume: 15,934
Last Updated: Tue 24 Dec 2024 02:59:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$5.70
13.03
0.70%
Fundamental analysis
26%
Profitability
25%
Dept financing
6%
Liquidity
50%
Performance
25%
Performance
5 Days
6.32%
1 Month
-30.18%
3 Months
363.28%
6 Months
5,557.58%
1 Year
2,877.67%
2 Year
1,358.59%
Key data
Stock price
$5.70
DAY RANGE
$18.73 - $18.73
52 WEEK RANGE
$0.31 - $36.00
52 WEEK CHANGE
$2,877.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Matthias G. Schroff
Region: US
Website: exicuretx.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: exicuretx.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Exicure, Inc. develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders.
Recent news